🚀 VC round data is live in beta, check it out!
Captor Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Captor Therapeutics and similar public comparables like Equillium, Prestige Biologics, StemRIM, Naturland Holding and more.
Captor Therapeutics Overview
About Captor Therapeutics
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
Founded
N/A
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$113M
Captor Therapeutics Financials
Captor Therapeutics reported last 12-month revenue of $6M and negative EBITDA of ($8M).
In the same LTM period, Captor Therapeutics generated ($8M) in EBITDA losses and had net loss of ($9M).
Revenue (LTM)
Captor Therapeutics P&L
In the most recent fiscal year, Captor Therapeutics reported revenue of $4M and EBITDA of ($9M).
Captor Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6M | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $3M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 67% | XXX | XXX | XXX |
| EBITDA | ($8M) | XXX | ($9M) | XXX | XXX | XXX |
| EBITDA Margin | (126%) | XXX | (208%) | XXX | XXX | XXX |
| EBIT Margin | (160%) | XXX | (246%) | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | (148%) | XXX | (243%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Captor Therapeutics Stock Performance
Captor Therapeutics has current market cap of $121M, and enterprise value of $113M.
Market Cap Evolution
Captor Therapeutics' stock price is $22.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $113M | $121M | -0.5% | XXX | XXX | XXX | $-1.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCaptor Therapeutics Valuation Multiples
Captor Therapeutics trades at 18.9x EV/Revenue multiple, and (15.0x) EV/EBITDA.
EV / Revenue (LTM)
Captor Therapeutics Financial Valuation Multiples
As of April 10, 2026, Captor Therapeutics has market cap of $121M and EV of $113M.
Equity research analysts estimate Captor Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Captor Therapeutics has a P/E ratio of (13.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV/Revenue | 18.9x | XXX | 26.0x | XXX | XXX | XXX |
| EV/EBITDA | (15.0x) | XXX | (12.5x) | XXX | XXX | XXX |
| EV/EBIT | (11.8x) | XXX | (10.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 38.8x | XXX | XXX | XXX |
| P/E | (13.8x) | XXX | (11.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (12.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Captor Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Captor Therapeutics Margins & Growth Rates
Captor Therapeutics' revenue in the last 12 month grew by 218%.
Captor Therapeutics' rule of 40 is 878% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Captor Therapeutics' rule of X is 2170% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Captor Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 218% | XXX | (59%) | XXX | XXX | XXX |
| EBITDA Margin | (126%) | XXX | (208%) | XXX | XXX | XXX |
| EBITDA Growth | (171%) | XXX | 27% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 878% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 2170% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 277% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 313% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Captor Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Equillium | XXX | XXX | XXX | XXX | XXX | XXX |
| Prestige Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| StemRIM | XXX | XXX | XXX | XXX | XXX | XXX |
| Naturland Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| NeOnc | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Captor Therapeutics M&A Activity
Captor Therapeutics acquired XXX companies to date.
Last acquisition by Captor Therapeutics was on XXXXXXXX, XXXXX. Captor Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Captor Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCaptor Therapeutics Investment Activity
Captor Therapeutics invested in XXX companies to date.
Captor Therapeutics made its latest investment on XXXXXXXX, XXXXX. Captor Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Captor Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Captor Therapeutics
| Where is Captor Therapeutics headquartered? | Captor Therapeutics is headquartered in Poland. |
| Is Captor Therapeutics publicly listed? | Yes, Captor Therapeutics is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Captor Therapeutics? | Captor Therapeutics trades under CTX ticker. |
| When did Captor Therapeutics go public? | Captor Therapeutics went public in 2021. |
| Who are competitors of Captor Therapeutics? | Captor Therapeutics main competitors are Equillium, Prestige Biologics, StemRIM, Naturland Holding. |
| What is the current market cap of Captor Therapeutics? | Captor Therapeutics' current market cap is $121M. |
| What is the current revenue of Captor Therapeutics? | Captor Therapeutics' last 12 months revenue is $6M. |
| What is the current revenue growth of Captor Therapeutics? | Captor Therapeutics revenue growth (NTM/LTM) is 218%. |
| What is the current EV/Revenue multiple of Captor Therapeutics? | Current revenue multiple of Captor Therapeutics is 18.9x. |
| Is Captor Therapeutics profitable? | No, Captor Therapeutics is not profitable. |
| What is the current EBITDA of Captor Therapeutics? | Captor Therapeutics has negative EBITDA and is not profitable. |
| What is Captor Therapeutics' EBITDA margin? | Captor Therapeutics' last 12 months EBITDA margin is (126%). |
| What is the current EV/EBITDA multiple of Captor Therapeutics? | Current EBITDA multiple of Captor Therapeutics is (15.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.